Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
President Donald Trump has reignited the debate over cannabis policy in Washington, D.C., by linking…
Pink-Runtz has solidified its status as a designer strain worth mastering. This 50% India, 50%…
Find the best THCA strains to smoke this 420 and beyond. Leafly reviewed popular THCA…
A fascinating new study published in the Journal of Hand Surgery Global Online has revealed…
The transfer of The Hawthorne Collective to a strategic partner was made in exchange for…
A vape cartridge is essentially the most important feature of any vape pen. The cart…